What are the diagnostic criteria, treatment options, and medication dosing considerations for Bipolar II disorder?

Bipolar II Disorder: Diagnosis and Treatment

For Bipolar II disorder, initiate treatment with lithium or lamotrigine as first-line mood stabilizers, with quetiapine as an alternative, particularly for acute depressive episodes which dominate the clinical picture at a 39:1 ratio over hypomanic episodes. 1, 2

Diagnostic Criteria

Bipolar II disorder requires at least one major depressive episode AND at least one hypomanic episode, with no history of full mania. 1, 3

Key Hypomanic Features to Identify:

• Duration: Minimum 4 days of symptoms (DSM-5 criteria)
• Mood: Elevated/euphoric OR irritable mood
• Core symptoms (need ≥3, or ≥4 if mood only irritable):
  • Decreased need for sleep
  • Increased goal-directed activity/overactivity (most reliable indicator)
  • Increased talkativeness
  • Racing thoughts
  • Grandiosity
  • Distractibility
  • Excessive risky behavior
• Critical distinction: Hypomania often increases functioning (unlike mania), does NOT cause marked impairment, does NOT require hospitalization, and has NO psychotic features 3

Diagnostic Pitfalls:

The 39:1 ratio of depressive to hypomanic episodes means patients typically present during depression and hypomania is missed, leading to misdiagnosis as major depressive disorder in up to 50% of depressed outpatients 1, 3. Probe specifically for overactivity and decreased sleep need during "good periods" rather than just asking about mood elevation. Use prospective mood charting and systematic screening tools 4.

Treatment Approach

Acute Hypomania

Treat hypomania even when associated with improved functioning, as depression typically follows the hypomania-depression cycle 3. Use:

• Lithium (FDA-approved for ages ≥12 years for acute mania/maintenance) 5
• Valproate (FDA-approved for acute mania in adults) 5
• Atypical antipsychotics: aripiprazole, olanzapine, risperidone, quetiapine, ziprasidone 5

Acute Bipolar II Depression

First-line options:

• Quetiapine monotherapy (FDA-approved for bipolar depression, including BD-II) 6, 2
• Mood stabilizer + antidepressant combination (NOT antidepressant monotherapy) 3, 4
• Lithium or lamotrigine 6, 2

Critical warning about antidepressants: While naturalistic studies show antidepressants may be effective in BD-II depression, one large controlled trial found them no better than placebo in bipolar depression 3. Antidepressant monotherapy risks worsening mixed features and mood destabilization 5, 3. If using antidepressants, always combine with a mood stabilizer and monitor for treatment-emergent affective switch (occurs in ≤19.9% of cases) 7.

Recent evidence (2025) shows venlafaxine and sertraline produced response rates of 60.4-73.3% and remission rates of 44.2-58.5% when used as monotherapy, with switch rates comparable to lithium 7. However, this contradicts guideline recommendations for combination therapy.

Maintenance Treatment

Lithium remains the gold standard with multiple controlled studies supporting prevention of both depression and hypomania recurrences 3, 4. Lamotrigine shows efficacy in delaying depression recurrences 3, 6.

Agents with bimodal stabilizing properties (lithium, carbamazepine, quetiapine) are most efficacious for long-term management 6.

Monitoring Requirements

For lithium:

• Baseline: Renal function (BUN, creatinine), thyroid function (TSH), pregnancy test, ECG (if cardiac risk factors)
• Ongoing: Serum levels (target 0.6-1.2 mEq/L), renal/thyroid function every 3-6 months 5

For valproate:

• Baseline: Liver function tests, complete blood count, pregnancy test
• Ongoing: Serum levels, hepatic/hematological indices every 3-6 months
• Warning: Risk of polycystic ovary disease in females 5

For atypical antipsychotics:

• Baseline: BMI, waist circumference, blood pressure, fasting glucose, fasting lipid panel
• BMI: Monthly for 3 months, then quarterly
• Blood pressure, fasting glucose, lipids: At 3 months, then yearly
• Monitor for extrapyramidal symptoms and tardive dyskinesia 5

Adjunctive Psychosocial Interventions

Always combine pharmacotherapy with psychotherapy to address functional impairment, medication adherence, and relapse prevention 5. Evidence supports:

• Psychoeducation (essential for all patients)
• Cognitive behavioral therapy (CBT)
• Interpersonal and social rhythm therapy (IPSRT) - focuses on stabilizing sleep/wake cycles and daily routines 8
• Family-focused therapy - improves treatment compliance and reduces relapse 5

Special Considerations

Comorbidities are the rule, not the exception: Anxiety disorders, substance use disorders, and cardiovascular disease are highly prevalent 1. Screen and treat these aggressively as they worsen prognosis.

Suicide risk in BD-II equals or exceeds BD-I 1. Maintain high vigilance and address suicidality proactively.

Avoid gabapentin and topiramate - controlled studies show no benefit 5.